Strongbridge Biopharma plc.
SBBP
SBBP was delisted on the 5th of October, 2021.
77 hedge funds and large institutions have $81.8M invested in Strongbridge Biopharma plc. in 2020 Q3 according to their latest regulatory filings, with 16 funds opening new positions, 26 increasing their positions, 23 reducing their positions, and 8 closing their positions.
100% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 8
13% more repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 23
12% more funds holding
Funds holding: 69 → 77 (+8)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
22% less capital invested
Capital invested by funds: $106M → $81.8M (-$23.7M)
53% less call options, than puts
Call options by funds: $37K | Put options by funds: $79K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
+$11.8M |
| 2 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$6.49M |
| 3 |
CC
Caxton Corporation
Princeton,
New Jersey
|
+$4.98M |
| 4 |
6CM
683 Capital Management
New York
|
+$3.83M |
| 5 |
GPCM
Granite Point Capital Management
Boston,
Massachusetts
|
+$3.71M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
-$785K |
| 2 |
Russell Investments Group
London,
United Kingdom
|
-$679K |
| 3 |
D.E. Shaw & Co
New York
|
-$306K |
| 4 |
Walleye Capital
New York
|
-$200K |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
-$144K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
76
Walleye Capital
New York
| – | -$200K | -52,961 | Closed |
|
77
Citadel Advisors
Miami,
Florida
| – | -$127K | -37,621 | Closed |
|
|
CI
78
Cigna Investments
Bloomfield,
Connecticut
| – | -$103K | -27,237 | Closed |
|
79
Walleye Trading
New York
| – | -$101K | -26,619 | Closed |
|
80
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
| – | -$97K | -24,589 | Closed |
|
81
SG Americas Securities
New York
| – | -$74K | -19,525 | Closed |
|
|
CG
82
Cutler Group
San Francisco,
California
| – | -$4K | -1,200 | Closed |
|
|
BCA
83
Berman Capital Advisors
Atlanta,
Georgia
| – | -$1.68K | -497 | -58% |
|
84
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | -$57 | -17 | -27% |
|
SBBP Hedge Fund Activity: Q3 2020 in Review
77 of the 4,957 institutional investors tracked by Wall St. Rank reported a position in Strongbridge Biopharma plc. (SBBP) for Q3 2020, worth a combined $81.8M — down 22% from $106M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new SBBP positions and 8 closed out — a net gain of 8 holders — while 26 added to existing stakes and 23 trimmed.
The largest buyer was OrbiMed, opening a new position worth an estimated $11.8M. The largest seller was JP Morgan Chase, cutting an estimated $785K.
- 77 institutional investors held Strongbridge Biopharma plc. (SBBP) as of Q3 2020, up from 69 in Q2 2020.
- Funds reported $81.8M of Strongbridge Biopharma plc. stock for Q3 2020, down 22% quarter-over-quarter.
- 16 funds opened new Strongbridge Biopharma plc. positions in Q3 2020 and 8 closed out, a net change of +8 holders.
- The largest Strongbridge Biopharma plc. buyer in Q3 2020 was OrbiMed, an estimated $11.8M added.
- The largest Strongbridge Biopharma plc. seller in Q3 2020 was JP Morgan Chase, an estimated $785K sold.
Based on aggregated 13F filings for Q3 2020.